With acquisition the most likely exit for today's biotech investors, it pays to keep current with the tastes of pharmaceutical firms when launching a venture.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Value drivers of development stage biopharma companies
The European Journal of Health Economics Open Access 17 January 2022
-
Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors
Therapeutic Innovation & Regulatory Science Open Access 11 January 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Big Pharma Mega-Mergers 1995–2014, http://www.datamonitor.com/kc/pharma/
Nutt, D. & Goodwin, G. Eur. Neuropsychopharmacol. 21, 495–499 (2011).
Tufts Center for the Study of Drug Development. Impact report: new or modified indications for existing drugs have steadily increased in U.S. 13(2) (Tufts University, March/April 2011).
Silicon Valley Bank. Continued rebound: trends in life science M&A. <http://www.svb.com/uploadedFiles/Blogs/10079/continued_rebound.pdf> (July 2012).
Daghlian, M. Life sciences M&A sees fewer billion dollar deals. The Burrill Report (4 January 2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.B., G-J.M. and S.v.D. are employed by Forbion Capital Partners.
Supplementary information
Rights and permissions
About this article
Cite this article
Giniatullina, A., Boorsma, M., Mulder, GJ. et al. Building for big pharma. Nat Biotechnol 31, 284–287 (2013). https://doi.org/10.1038/nbt.2533
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2533
This article is cited by
-
Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors
Therapeutic Innovation & Regulatory Science (2022)
-
Value drivers of development stage biopharma companies
The European Journal of Health Economics (2022)
-
Stepping to the exit
Nature Biotechnology (2021)
-
Trade-sale exits in different biotech sectors
Nature Biotechnology (2015)
-
Acquiring orphans
Nature Biotechnology (2014)